|
- Ascendis Pharma: Patients. Science. Passion.
Our unwavering focus Ascendis Pharma is a global biopharmaceutical company committed to making a meaningful difference in patients’ lives
- Pipeline - Ascendis Pharma
Our pipeline of innovative new therapies is driven by the flexibility of our TransCon technologies and our aim to improve patients' lives Ascendis and its partners have multiple prodrug therapies in development Each product candidate is unique and designed to be a best-in-class therapy
- About Us - Ascendis Pharma
Ascendis Pharma was founded in 2007 based on the innovative TransCon technology platform We are headquartered in Copenhagen, Denmark and are publicly traded, following an initial public offering in 2015 (Nasdaq: ASND) We have employees working across the globe to improve patients’ lives
- Careers | Ascendis Pharma
As Ascendis grows, we are always looking to connect with individuals who are passionate about making a meaningful difference for patients If you don’t see an open role that fits your skills and would like to be considered for future opportunities, we encourage you to upload your resume to our country-specific talent pools listed here:
- Contact Us | Ascendis Pharma
Ascendis is headquartered in Denmark and has offices in Germany and in Palo Alto, CA , Princeton, NJ in the U S
- Technology - Ascendis Pharma
At the core of Ascendis Pharma is a powerful, flexible technology platform that uses advanced knowledge of chemistry to overcome challenges of developing new therapeutics When applied using known biology, this technology platform helps us address unmet patient needs in unprecedented ways
- OUR PRODUCTS - Ascendis Pharma
Ascendis Pharma medicines using TransCon technology are authorized for the indications and in the countries or regions shown below Please note that in some countries, a medicine may be authorized for marketing but not yet commercially available
- Endocrinology | Ascendis Pharma
We built our first pipeline in Endocrinology Rare Diseases because it is an area where we saw the potential of TransCon technology to address unmet medical needs – for example, replacing missing hormones in a predictable manner while extending their duration of action to potentially improve therapeutic effects Each of our endocrinology product candidates – TransCon hGH, TransCon PTH, and
|
|
|